Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ghulam J Mufti

Showing results (1-10 of 224) with videos related to

Pageof 23
Sort By:
Best Practice & Research. Clinical Haematology|October 21, 2004
Pathobiology, classification, and diagnosis of myelodysplastic syndromeGhulam J Mufti
Reviews in Clinical and Experimental Hematology|July 20, 2005
Emerging therapeutic and supportive care approaches for the myelodisplastic syndromesGhulam J Mufti
Therapeutics and Clinical Risk Management|March 25, 2008
Azacytidine (Vidaza(R)) in the treatment of myelodysplastic syndromesKavita Raj, Ghulam J Mufti
British Journal of Haematology|November 20, 2008
Van-den Berghe's 5q- syndrome in 2008Azim Mohamedali, Ghulam J Mufti
Hematology. American Society of Hematology. Education Program|December 13, 2012
Myelodysplastic syndromes: who and when in the course of disease to transplantGhulam J Mufti, Victoria Potter
Current Hematology Reports|August 7, 2003
Apoptosis in the myelodysplastic syndromesNigel B Westwood, Ghulam J Mufti
Current Opinion in Oncology|September 11, 2014
Allogeneic haematopoietic stem cell transplantation in myelodysplastic syndromesEmily Bart-Smith, Ghulam J Mufti
Nature Clinical Practice. Oncology|December 13, 2005
Myelodysplastic syndromes (MDSs) and acute myelogenous leukemia (AML) comprise a closely linked continuum of malignant hematologic diseases. IntroductionStephen B Baylin, Ghulam J Mufti
Nature Clinical Practice. Oncology|December 13, 2005
Methylation inhibitor therapy in the treatment of myelodysplastic syndromeLewis R Silverman, Ghulam J Mufti
International Journal of Hematology|August 16, 2001
The role of apoptosis in the pathogenesis of the myelodysplastic syndromesJane E Parker, Ghulam J Mufti
Pageof 23

Showing results (1-10 of 224) with videos related to

Sort By:
Pageof 23
Best Practice & Research. Clinical Haematology|October 21, 2004
Pathobiology, classification, and diagnosis of myelodysplastic syndromeGhulam J Mufti
Reviews in Clinical and Experimental Hematology|July 20, 2005
Emerging therapeutic and supportive care approaches for the myelodisplastic syndromesGhulam J Mufti
Therapeutics and Clinical Risk Management|March 25, 2008
Azacytidine (Vidaza(R)) in the treatment of myelodysplastic syndromesKavita Raj, Ghulam J Mufti
British Journal of Haematology|November 20, 2008
Van-den Berghe's 5q- syndrome in 2008Azim Mohamedali, Ghulam J Mufti
Hematology. American Society of Hematology. Education Program|December 13, 2012
Myelodysplastic syndromes: who and when in the course of disease to transplantGhulam J Mufti, Victoria Potter
Current Hematology Reports|August 7, 2003
Apoptosis in the myelodysplastic syndromesNigel B Westwood, Ghulam J Mufti
Current Opinion in Oncology|September 11, 2014
Allogeneic haematopoietic stem cell transplantation in myelodysplastic syndromesEmily Bart-Smith, Ghulam J Mufti
Nature Clinical Practice. Oncology|December 13, 2005
Myelodysplastic syndromes (MDSs) and acute myelogenous leukemia (AML) comprise a closely linked continuum of malignant hematologic diseases. IntroductionStephen B Baylin, Ghulam J Mufti
Nature Clinical Practice. Oncology|December 13, 2005
Methylation inhibitor therapy in the treatment of myelodysplastic syndromeLewis R Silverman, Ghulam J Mufti
International Journal of Hematology|August 16, 2001
The role of apoptosis in the pathogenesis of the myelodysplastic syndromesJane E Parker, Ghulam J Mufti
Pageof 23